Immuno-Oncology

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Primo N. Lara Jr, MD, discusses the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, discusses PD-L1 testing and the development of biomarkers for PD-L1 antibodies for patients with urothelial carcinoma.

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

The therapeutic paradigm continues to evolve in advanced non-small cell lung cancer, with increased emphasis being placed on rational combinations and biomarkers in the next few years.

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.